CellProtect Nordic Pharmaceuticals AB develops new cell-based therapies for treatment of severe diseases. The company is privately owned and supported by 20 working shareholders with extensive experience from the life science industry.
CellProtect Nordic Pharmaceuticals AB has developed an IP-protected process for GMP manufacturing of the NK-cell based drug candidate CellProtect for treatment of multiple myeloma. There are solid preclinical data showing that NK-cells expanded with the patented technology have restored cytotoxic activity and ability to selectively kill myeloma tumour cells. A Phase I / II clinical trial in multiple myeloma patients has been performed where CellProtect has been studied as an adjunct therapy to autologous stem cell transplantation. The results are very promising and CellProtect in the clinical trials shows a good safety profile. CellProtect was recently granted orphan drug designation from the European Commission for the treatment of multiple myeloma.
CellProtect Nordic Pharmaceuticals AB develops also therapies based on other cell types such as foetal mesenchymal stem cells.